Allergan partners with SonarMD
Allergan announced a collaboration with SonarMD, a leader in population health management, on the development of clinical decision support and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea in clinical practice and monitor their treatment outcomes. Moreover, the companies will establish a patient engagement platform which can be used to evaluate symptoms and health outcomes among patients with IBS-D in a real-world clinical setting. Allergan and SonarMD will leverage the Sonar platform for use with IBS-D patients with the goal of optimizing efficient diagnosis and effective use of treatment options to manage IBS-D in clinical practice. This represents the first application of the SonarMD platform for IBS.